Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy in Patients With Limited Progression on Immune Checkpoint Blockade
NCT03693014Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2018
- Primary completion
- Oct 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in metastatic cancer, melanoma, lung cancer and 3 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Overall Response Rate at 24 weeks. Started Oct 2018; status: active, not recruiting.
02
Conditions
metastatic cancermelanomalung cancerbladder cancerrenal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT03693014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03693014.